Pfizer coronavirus vaccine candidate shows early promise

By Cassidy Morrison

Published July 1, 2020 2:41pm ET

Add Washington Examiner on Google

Pfizer coronavirus vaccine candidate shows early promise — A lab technician working a bottle containing for COVID-19 vaccine testing at Chula Vaccine Research Center, run by Chulalongkorn University in Bangkok, Thailand, Monday, May 25, 2020. Thai health officials said that scientists in Thailand have had promising results in testing a COVID-19 vaccine candidate on mice, and have begun testing on monkeys. | (Sakchai Lalit/AP)

A coronavirus vaccine candidate from pharmaceutical company Pfizer has shown potential in healthy volunteers. Stocks jumped on the announcement Wednesday.

The experimental vaccine developed by Pfizer and the biotech firm BioNTech produced promising results in early-stage human trials, in which 45 volunteers were given doses of the vaccine. Each participant received 10, 30, or 100 microgram doses of the vaccine or a placebo.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

COVID-19 Pharmaceutical Industry Trump Administration Vaccines